Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
10.1016/j.apsb.2020.06.012
- Author:
Wei SHI
1
;
Weiwei JIN
2
;
Linghui XIA
1
;
Yu HU
1
Author Information
1. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
2. Department of Cardiovascular, Optical Valley School District, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan 430061, China.
- Publication Type:Review
- Keywords:
AML;
Allogeneic hematopoietic stem cell transplantation;
Immune microenvironment;
Metabolism;
Oncogenic effectors;
Relapse;
Surface markers;
Targeted therapy
- From:
Acta Pharmaceutica Sinica B
2020;10(11):2125-2139
- CountryChina
- Language:English
-
Abstract:
Relapse remains the worst life-threatening complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML), whose prognosis has been historically dismal. Given the rapid development of genomics and immunotherapies, the interference strategies for AML recurrence have been changing these years. More and more novel targeting agents that have received the U.S. Food and Drug Administration (FDA) approval for
